Prevention and treatment of thrombosis in cancer and oncohematological patients
The purpose of the review is to highlight the current possibilities for the prevention and treatment of venous thrombotic complications in patients with cancer.The data of 52 scientific sources published in the Russian and foreign press in 1997–2020 are considered.Cancer patients are at high risk of...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241332810252288 |
|---|---|
| author | O. V. Somonova A. L. Elizarova T. V. Davydova |
| author_facet | O. V. Somonova A. L. Elizarova T. V. Davydova |
| author_sort | O. V. Somonova |
| collection | DOAJ |
| description | The purpose of the review is to highlight the current possibilities for the prevention and treatment of venous thrombotic complications in patients with cancer.The data of 52 scientific sources published in the Russian and foreign press in 1997–2020 are considered.Cancer patients are at high risk of thrombotic complications, which worsen the outcome of anticancer treatment and are one of the leading causes of death. Thrombosis in an oncological patient increases the risk of death by 30 times, which is associated with fatal thromboembolism and a more aggressive course of the disease. The leading role in the pathogenesis of thrombotic complications is played by disorders in the hemostasis system caused both by the tumor itself and by therapy. Low molecular weight heparins are considered the basis for specific prophylaxis of thromboembolic complications in cancer patients. The use of low molecular weight heparins after surgery and during chemotherapy effectively reduces the incidence of venous thrombosis. Direct oral anticoagulants are promising drugs for oral administration and are indicated as one of the treatment options for patients with tumor-associated thrombosis with a low risk of bleeding and no drug interactions with ongoing systemic chemotherapy. |
| format | Article |
| id | doaj-art-5ab919f5a07542d78378efdf409cba86 |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2021-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-5ab919f5a07542d78378efdf409cba862025-08-20T04:00:13ZrusABV-pressОнкогематология1818-83462413-40232021-11-0116410.17650/1818-8346-2021-16-4-40-49410Prevention and treatment of thrombosis in cancer and oncohematological patientsO. V. Somonova0A. L. Elizarova1T. V. Davydova2N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaThe purpose of the review is to highlight the current possibilities for the prevention and treatment of venous thrombotic complications in patients with cancer.The data of 52 scientific sources published in the Russian and foreign press in 1997–2020 are considered.Cancer patients are at high risk of thrombotic complications, which worsen the outcome of anticancer treatment and are one of the leading causes of death. Thrombosis in an oncological patient increases the risk of death by 30 times, which is associated with fatal thromboembolism and a more aggressive course of the disease. The leading role in the pathogenesis of thrombotic complications is played by disorders in the hemostasis system caused both by the tumor itself and by therapy. Low molecular weight heparins are considered the basis for specific prophylaxis of thromboembolic complications in cancer patients. The use of low molecular weight heparins after surgery and during chemotherapy effectively reduces the incidence of venous thrombosis. Direct oral anticoagulants are promising drugs for oral administration and are indicated as one of the treatment options for patients with tumor-associated thrombosis with a low risk of bleeding and no drug interactions with ongoing systemic chemotherapy.https://oncohematology.abvpress.ru/ongm/article/view/503cancer patientthrombotic complicationlow molecular weight heparindirect oral anticoagulant |
| spellingShingle | O. V. Somonova A. L. Elizarova T. V. Davydova Prevention and treatment of thrombosis in cancer and oncohematological patients Онкогематология cancer patient thrombotic complication low molecular weight heparin direct oral anticoagulant |
| title | Prevention and treatment of thrombosis in cancer and oncohematological patients |
| title_full | Prevention and treatment of thrombosis in cancer and oncohematological patients |
| title_fullStr | Prevention and treatment of thrombosis in cancer and oncohematological patients |
| title_full_unstemmed | Prevention and treatment of thrombosis in cancer and oncohematological patients |
| title_short | Prevention and treatment of thrombosis in cancer and oncohematological patients |
| title_sort | prevention and treatment of thrombosis in cancer and oncohematological patients |
| topic | cancer patient thrombotic complication low molecular weight heparin direct oral anticoagulant |
| url | https://oncohematology.abvpress.ru/ongm/article/view/503 |
| work_keys_str_mv | AT ovsomonova preventionandtreatmentofthrombosisincancerandoncohematologicalpatients AT alelizarova preventionandtreatmentofthrombosisincancerandoncohematologicalpatients AT tvdavydova preventionandtreatmentofthrombosisincancerandoncohematologicalpatients |